180 Life Sciences Corp. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by 180 Life Sciences Corp. (NASDAQ: ATNF) on December 8, 2021. The registrant is an emerging growth company incorporated in Delaware. The report details executive compensation arrangements and equity grants approved by the Board of Directors effective December 8, 2021.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data disclosed relates to specific equity transactions:
- Stock Option Exercise Price: $3.95 per share (closing sales price on the grant date).
- Direct Stock Issuance: 5,536 shares issued to Sir Marc Feldmann valued at $3.95 per share, totaling $21,870 in compensation.
Material Changes and Executive Actions
The Board approved the following equity awards under the 2020 Omnibus Incentive Plan:
- Quan Anh Vu (New COO/CBO): Granted 275,000 Incentive Stock Options (ISOs). Vesting occurs over 48 equal monthly installments starting November 2021. Subject to the $100,000 annual vesting limit for ISOs.
- Jonathan Rothbard (Chief Science Officer): Granted 300,000 ISOs. Vesting includes 1/3rd at grant and the remainder over 24 monthly installments starting December 31, 2021. Subject to the $100,000 annual vesting limit for ISOs.
- Dr. Lawrence Steinman and Sir Marc Feldmann (Executive Co-Chairmans): Each granted 25,000 Non-Qualified Stock Options (NQSOs) vesting immediately.
- Board Compensation: Sir Marc Feldmann received 5,536 shares of common stock to settle $21,870 in accrued board compensation.
All options have a 10-year term and include accelerated vesting provisions for death, disability, termination without cause, good reason, or change of control.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, financial outlook, or specific risk factors beyond the standard vesting conditions tied to continued service and corporate events (e.g., change of control).
Key Facts for Investor Verification
- Verify the total number of shares authorized under the 2020 Omnibus Incentive Plan to assess dilution impact from these grants.
- Confirm the current trading price of ATNF relative to the $3.95 exercise price to determine if options are in-the-money.
- Review the Company's most recent 10-K or 10-Q for actual revenue and cash position, as this 8-K contains no operational financial data.
- Monitor the vesting schedule for Mr. Vu and Mr. Rothbard to understand future equity dilution over the next 4 years.